1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Delphi initiative for early-onset colorectal cancer (DIRECt) international management guidelines
    Guidelines

    Cavestro, G. M.; Mannucci, A.; Balaguer, F.; Hampel, H.; Kupfer, S. S.; Repici, A.; Sartore-Bianchi, A.; Seppälä, T. T.; Valentini, V.; Boland, C. R.; more...
    Clinical Gastroenterology and Hepatology (2023)

    Fulltext@MSK | Save
  • Exposure-response analyses of tremelimumab monotherapy or in combination with durvalumab in patients with unresectable hepatocellular carcinoma
    Journal Article

    Song, X.; Kelley, R. K.; Khan, A. A.; Standifer, N.; Zhou, D.; Lim, K.; Krishna, R.; Liu, L.; Wang, K.; McCoon, P.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Induction FOLFOX and PET-directed chemoradiation for locally advanced esophageal adenocarcinoma
    Journal Article

    Carr, R. A.; Hsu, M.; Harrington, C. A.; Tan, K. S.; Bains, M. S.; Bott, M. J.; Ilson, D. H.; Isbell, J. M.; Janjigian, Y. Y.; Maron, S. B.; more...
    Annals of Surgery (2023)

    Fulltext@MSK | Save
  • Treatment of Metastatic Colorectal Cancer: ASCO Guideline
    Guidelines

    Morris, V. K.; Kennedy, E. B.; Baxter, N. N.; Benson, A. B. 3rd; Cercek, A.; Cho, M.; Ciombor, K. K.; Cremolini, C.; Davis, A.; Deming, D. A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in first-line treatment of claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase 2, open-label, randomized study
    Meeting Abstract

    Park, W.; O'Reilly, E. M.; Furuse, J.; Li, C. P.; Oh, D. Y.; Garcia-Carbonero, R.; Roth, G.; Lee, H. J.; Bhattacharya, P. P.; Moran, D. M.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • The SHARON trial: A study of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous stem cell rescue for metastatic pancreatic cancer with an inherited BRCA mutation
    Meeting Abstract

    Yu, K. H.; Weekes, C. D.; Chen, Y. B. A.; Glazier, J. A.; Glazier, A.; Dahi, P.; Giralt, S.; O'Reilly, E. M.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • APOLLO: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2 mutation—ECOG-ACRIN EA2192
    Meeting Abstract

    Reiss, K. A.; Hong, S. C.; Kasi, A.; O'Reilly, E. M.; Maithel, S. K.; Yao, X.; Hamilton, S. R.; Boursi, B.; Pishvaian, M. J.; Klempner, S. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) and biomarkers in daNIS-2, a phase III study comparing NIS793 plus nab-paclitaxel/gemcitabine (NG) vs placebo plus NG in first-line (1L) metastatic pancreatic ductal adenocarcinoma (mPDAC)
    Meeting Abstract

    Wainberg, Z. A.; Macarulla, T.; Golan, T.; Ikeda, M.; Milella, M.; Taieb, J.; Wang, L.; Gyambibi, N.; López, E. M.; Bento Pereira da Silva, A.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Trial in progress: A phase 1, first-in-human, open-label, multicenter, dose-escalation and dose-expansion study of ASP3082 in patients with previously treated advanced solid tumors and KRAS G12D mutations
    Meeting Abstract

    Tolcher, A. W.; Park, W.; Wang, J. S.; Spira, A. I.; Janne, P. A.; Lee, H. J.; Gill, S.; LoRusso, P.; Herzberg, B.; Goldman, J. W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) and biomarker assessments in daNIS-3, a phase II platform study of NIS793 (anti–TGF-β monoclonal antibody) and other investigational drug combinations with standard of care (SOC) vs SOC alone in patients (pts) with second-line metastatic colorectal cancer (mCRC)
    Meeting Abstract

    Kopetz, S.; Kasper, S.; Rivera, F.; Tournigand, C.; Cheng, Y.; Deshpande, P.; D'Alessio, D.; Amirouchene Angelozzi, N.; Bento Pereira da Silva, A.; Segal, N. H.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save